Sample output from the Growth Opportunity Analysis & Execution Plan prompt in the Sonar AI Prompt Library, run against a NetSuite test account. Every name and number here is test data. Back to the post · The library

Growth Strategy & Execution Plan

A data-driven strategic assessment of the multinational manufacturing group on NetSuite account TD3092577. v3 adds a per-subsidiary P&L — which materially changes the margin story and locates the management fee — plus two companion data exports (full backlog triage list, complete A/R aging by customer).

Prepared from live ERP data  •  August 9, 2026  •  Senior Business Strategy Review  •  Print-ready (Ctrl/Cmd+P)

1.The Business at a Glance

A mid-market discrete manufacturer and distributor of electronic and industrial components — fan assemblies, flex circuit boards, hydraulic/vacuum pumps, solder materials, medical devices (portable ultrasound), and contract-manufactured goods. It runs a "make-in-Vietnam, sell-in-US" model: the Vietnam plant supplies the US distribution entity, with satellite subsidiaries in Canada, UK, Germany/Ireland, Japan, and Russia (several dormant; China already deactivated).

$20.7M
2026 GL revenue YTD
$7.1M
External revenue YTD (ex-IC)
44×
External monthly run-rate growth since Jan 2025
204
Active employees
467
Customer records (151 active buyers)
632
Inventory SKUs + 116 assemblies

External revenue by month (intercompany removed)

The real growth story: ~$25K/month in early 2025 → $1.1M/month in Aug 2026. GL headline figures are inflated by a ~$9.8M intercompany Vietnam→US transfer booked in May 2026 — excluded here.
$0 $640K $1.28M J25 M M J S N J26 M M J $1.11M $1.28M

External customer concentration (2025→YTD)

Top-5 external accounts ≈ 31% of external revenue — diversified for the size, no single account above ~12%.
31% top 5 share Abbott Inc. — $977K Dolor Tempus — $456K Smith Supplies — $428K Photolist Fdn — $315K Chatterpoint — $297K All others — ~69%

Target audience / client base

  • B2B industrial OEMs & distributors — components (motors, PCBs, power cords) and assemblies, repeat orders on credit terms.
  • Contract-manufacturing clients — tolling, outside processing, and contract-MFG items are consistent top sellers.
  • Medical/technical equipment buyers — portable ultrasound, serialized sub-assemblies, warranty-tracked.
  • Funnel shape: 467 customer records → only ~167 have ever been invoiced → 151 bought in 2026. The base is mostly ~300 never-activated prospects, not lapsed customers — an acquisition problem, not a churn problem.

2.Financial Health & Budget Reality

Top-line growth is real and steep. The consolidated P&L looks fragile — but the subsidiary view (§2b) shows the weakness is structural and intercompany, not commercial: the trading entities are healthy and profitable; the group result is dragged down by a $4.66M management fee booked in Vietnam.

35–36%
True GM at distribution entities
−$0.9M
2026 consolidated operating result
$1.30M
External A/R overdue (71% of open)
$3.25M
Order backlog awaiting fulfillment
$1.76M
Backlog stuck >90 days
Analyst's correction vs. v2: the consolidated "27.9% gross margin" reported earlier is not reliable. Vietnam's COGS accounts carry a ~$23.3M intercompany purchases credit (manufacturing/transfer postings), which pollutes any group-level COGS roll-up. Measured at the entity level, where the accounting is clean, the distribution subsidiaries earn ~35–36% gross margin and the flagship US entity substantially more. Margin repair (opportunity #5) remains valid but is re-aimed: the problem is not underpricing across the board — it is transfer-pricing structure and the management fee, plus selective SKU-level leaks.

Where the operating budget actually goes (2026 YTD)

Mgmt fees (in VN)
$4.66M
Salaries (G&A)
$587K
Rent
$325K
D&A
$313K
Commissions
$227K
Advertising
$85K ⚠
Budget insight — demand generation is starved: advertising is $85K (~1.2% of external revenue) vs. an industrial-peer norm of 1.5–3%. Meanwhile $4.66M flows out as management fees — the single biggest lever in the cost base. Reallocating even ~$150–200K into targeted demand gen is a 2.5× increase on today's spend, fundable entirely from A/R recovery.

External A/R aging (intercompany excluded) — $1.82M open

The bulge is 31–90 days — recoverable with normal collections pressure. Only $422K has aged past 90 days; ~$11K past a year. The separate $9.77M intercompany balance (66 days) needs a netting decision, not dunning. Full per-customer detail: ar-aging-by-customer.csv (§8).
Current
$520K
1–30 days
$71K
31–60 days
$521K
61–90 days
$287K
91–365 days
$411K
> 1 year
$11K

Fulfillment backlog aging — 691 open orders / $3.25M

125 orders (>$1.75M) unshipped for over 90 days against 3.7M units on hand — process, not stock. Oldest order (SO1806, Rhynyx Associates) is 395 days old. Full order-by-order triage list: backlog-triage-open-sales-orders.csv (§8).
0–30 days
325 orders
31–90 days
241 orders
91–180 days
92 orders
> 180 days
33 orders

2b.Per-Subsidiary P&L — Where the Money Is Actually Made

2026 YTD, posted GL, split by transaction-line subsidiary. This view resolves the consolidated puzzle: the trading entities are all profitable; the group loss lives in the Vietnam entity's management fee and HQ overhead.

SubsidiaryRevenueCOGSGross marginOpexOperating incomeRead
United States$7,581,244$3,038,86359.9%$1,149,504+$3,392,877Profit engine
US-2$1,926,809$1,228,62336.2%$463,124+$235,062Healthy
United Kingdom$751,389$488,67735.0%$158,593+$104,119Healthy, small
Canada$751,389$489,77734.8%$170,370+$91,242Healthy, small
Headquarters$5,523$238,794−$229,968Corporate cost
Vietnam$9,767,441 100% ICdistorted*n/m$4,651,164n/mFee + transfer hub
Germany / Japan / Russia / Ireland~$0~$0~$0~$0Dormant shells

*Vietnam's COGS accounts net to a ~$20.2M credit (a $23.3M intercompany "Purchases" credit less $3.0M finished-goods COGS) — manufacturing/transfer-pricing postings that only make sense post-elimination. Its revenue is 100% the intercompany sale to the US. Its $4.65M opex is almost entirely the group management fee ($4.66M account total).

Operating income by entity (2026 YTD, trading entities + HQ)

United States
+$3.39M
US-2
+$235K
United Kingdom
+$104K
Canada
+$91K
Headquarters
−$230K
VN mgmt fee
−$4.65M
Three strategic conclusions from the subsidiary view:

3.Challenges & Competitive Landscape

Internal challenges (from the data)

  • Cash $1.30M external A/R overdue + $9.77M intercompany unsettled; dunning configured but not enforced.
  • Fulfillment 691 orders / $3.25M pending; $1.76M aged >90 days; oldest 395 days.
  • Structure $4.66M management fee > combined trading profit; consolidated loss despite healthy entities.
  • Funnel 117 estimates, zero tracked conversions; pipeline $118K vs. $13M+ external run-rate.
  • Activation ~300 customer records never purchased; only 16 genuinely lapsed buyers.
  • Quality 35 return authorizations ($120K) in 2026; an account literally named "Alpha Demand (Late Delivery)".
  • Geo Germany/Japan/Russia dormant; Russia carries geopolitical risk.

Competitive / market context

The ERP doesn't name competitors; product mix places the firm against these archetypes:

  • Global EMS/CM giants (Jabil, Flex, Sanmina) — win on scale. Counter: responsiveness, small batches, specialized assemblies.
  • Broadline distributors (Digi-Key, Mouser, Grainger-types) — win on availability & e-commerce. The 90-day backlog is a direct liability against them.
  • Regional Asian CMs — win on cost. The Vietnam hub keeps this firm competitive as buyers diversify from China (its own China entity is already inactive — consistent with the shift).
  • Structural advantages to press: Vietnam cost base + US inventory (3.7M units / 602 SKUs), serialized & warranty-tracked capability (medical), end-to-end make-to-order (work orders, BTO), and now-proven transplantability of the model to UK/Canada.

4.Growth Opportunities — Ranked by ROI × Difficulty

Ranked by expected 12-month cash/profit impact relative to effort. The subsidiary P&L promotes the management-fee renegotiation from a Phase-3 side item to a top-tier opportunity in its own right.

#Opportunity12-mo impact est.DifficultyROI rank
1A/R recovery & credit discipline — enforce dunning on $1.30M external overdue; settle $9.77M intercompany; credit holds >60d$0.9–1.1M cashLow★★★★★
2Clear the fulfillment backlog — ship & bill 691 pending orders; confirm-or-cancel the 33 >180 days; fix the pick/pack constraint$2–3M revenue pull-forwardMedium★★★★★
3Management-fee restructuring — renegotiate the $4.66M group charge (basis, timing, or performance link); it exceeds all trading profit combined$1–2M retained profitMedium†★★★★★
4Fix the quote-to-order funnel — convert/track the 117 open estimates, instrument the pipeline, 48h quote SLA$0.8–1.5M revenueMedium★★★★
5Activate the prospect base & grow share-of-wallet — 300 never-purchased records + 16 lapsed buyers + expansion in the 151 actives$0.7–1.5M revenueMedium★★★★
6SKU-level margin repair — reprice leaking SKUs, freight audit, mix-shift toward assemblies & contract-MFG services (entity GMs already 35%+)+1–2 pts GM ≈ $150–300KMedium★★★
7Demand generation investment — 0.4% → 1.5% of revenue, targeted at contract-MFG and medical-device niches; gated on #4$1–2M pipeline (lagging)Medium★★★
8Scale UK & Canada; rationalize the rest — both run 35% GM profitably at tiny scale; Germany/Japan dormant; Russia wind-down$0.5–1.5M revenueHigh★★★

†Politically medium-to-hard — it is an intra-group negotiation, but the subsidiary P&L gives management the data to make the case.

OPPORTUNITY #1 — HIGHEST ROI

Cash Recovery Engine

Low difficulty 30–60 day payback

The dunning module (levels, templates, procedures) is already configured — enforcement is the gap. The $1.30M overdue bulge sits at 31–90 days, the sweet spot where normal pressure recovers 70–85%. This cash funds every other initiative without external capital.

OPPORTUNITY #2

Backlog-to-Cash Sprint

Medium difficulty 60–90 days

691 orders pending against 3.7M units on hand is a process constraint. Wave picking only went live May 2026 — the operation is mid-transition. The triage CSV (§8) classifies every order by age bucket, with >180-day orders pre-flagged for confirm-or-cancel.

OPPORTUNITY #3 — NEW IN V3

Management-Fee Restructuring

Medium difficulty Flips group P&L positive

The $4.66M fee booked in Vietnam exceeds the combined $3.8M operating profit of every trading entity. No commercial initiative on this list moves the consolidated bottom line as much as restructuring this single intra-group charge.

OPPORTUNITY #4

Funnel Instrumentation & Conversion

Medium difficulty Gates #7

Zero of 117 estimates show linked orders — quotes die silently or reps bypass the record flow. Mandate estimate→SO transformation, a 48-hour quote SLA, and weekly pipeline review. Scaling demand gen into a leaky funnel wastes the budget.

5.12-Month Execution Roadmap

Phase 1 · Days 0–30 — "Stop the bleeding"

Cash & Credibility

  • A/R war room: assign owner; work the aging CSV top-down (Chatterpoint $255K/426d, Meetz $220K/92d, Rhynyx $152K/302d, Monrovia $120K, Abbott $106K/1,036d); activate dunning for everything 30+ days.
  • Reserve/write-off review for balances >365 days (Abbott, American Food $70K/945d).
  • Settle intercompany: clear the $9.77M Vietnam→US balance; set monthly netting cadence.
  • Backlog triage: work the triage CSV — stock-available / awaiting-build / blocked; confirm-or-cancel all 33 orders >180 days (starting with SO1806 at 395 days); ship everything pickable this month.
  • Credit policy: new-order credit holds for accounts >60 days past due.

Exit criteria external overdue < $700K · 200+ backlog orders shipped · aged balances reserved · >180d orders resolved

Phase 2 · Days 31–90 — "Fix the machine"

Throughput & Funnel

  • Fulfillment constraint fix: root-cause the backlog (wave picking adopted only May 2026); order-to-ship SLA ≤ 5 days; daily shipped-vs-booked dashboard.
  • Quote discipline: mandatory estimate→SO transformation in NetSuite; 48h quote SLA; weekly pipeline review; win/loss reasons on every closed estimate.
  • Pricing review wave 1: SKU-level margin audit at the entity level (clean data); kill or reprice negative-margin lines; freight recovery check.
  • Reactivation outreach: rep-led contact with the 16 lapsed buyers (named list, §8); automated nurture launch for the ~300 never-activated prospects.
  • Returns root-cause: analyze the 35 RAs; the "Late Delivery" account flag ties returns risk directly to the backlog problem.
  • Prepare the management-fee case: assemble the subsidiary P&L evidence pack (§2b) for the group negotiation in Phase 3.

Exit criteria backlog < 200 orders · quote conversion measurable & >25% · fee negotiation scheduled

Phase 3 · Days 91–180 — "Reinvest in growth"

Demand, Margin & the Fee

  • Management-fee renegotiation: the headline event of this phase — restructure basis/timing or convert part to performance-linked. Success flips consolidated P&L positive on its own.
  • Demand-gen launch (~$150–200K, funded by recovered cash): position around Vietnam-based contract manufacturing + US stock availability; target electronics OEMs and medical-device firms diversifying from China. Hard gate: only if Phase-2 funnel instrumentation is live.
  • Mix shift: sales incentives weighted toward assemblies, kits, contract-MFG services.
  • Key-account program for top 20 external customers (QBRs, forecast sharing, sell-side blanket orders — 7 blanket POs already prove the mechanism on the buy side).

Exit criteria fee restructured or escalated · $1M+ new qualified pipeline · 25+ newly activated accounts

Phase 4 · Days 181–365 — "Scale what works"

Expansion & Structure

  • Scale UK & Canada: both proven at ~35% GM — fund country plans (local rep, targeted demand gen, sell-side blankets) with a $1.5M combined revenue target for 2027.
  • Rationalize the rest: Germany/Ireland and Japan — commercialize with a concrete plan or consolidate; Russia — wind-down assessment given risk profile.
  • Contract-MFG productization: package tolling/outside-processing into marketed offerings with standard lead times.
  • Capacity planning: Vietnam plant loading and US warehouse capacity 2027 plan; inventory rationalization of the 3.7M-unit position (slow-mover cash release).

Exit criteria external run-rate ≥ $16M · consolidated operating income positive · subsidiary decisions executed

6.Key Risks & Mitigations

RiskLikelihoodImpactMitigation
Management-fee renegotiation fails (group politics)MediumConsolidated loss persists despite healthy entitiesLead with the §2b evidence pack; propose performance-linked structure rather than pure reduction; escalate with trading-entity data
Aged A/R proves uncollectible (Abbott 1,036d, American Food 945d)Medium$150–300K write-offReserve now; payment plans before legal; price lesson into credit policy
Backlog reflects capacity, not process — can't ship fasterMediumRevenue slips; churn worsensPhase-1 triage separates stock vs. build constraints before committing SLAs
Aggressive dunning damages key relationshipsMediumLoss of top accountsWhite-glove top-20; automation only below that tier
Margin pressure from input costs (Vietnam wages, freight)MediumEntity GM erodes below 35%Quarterly pricing cadence; contract-MFG mix shift; freight renegotiation
Demand-gen spend outruns funnel fixesMediumWasted budgetHard gate: no Phase-3 spend until conversion is instrumented
Geopolitical exposure (Russia entity, Asia supply chain)Low–MedCompliance / disruptionPhase-4 wind-down assessment; dual-source critical components

7.Scorecard — Metrics That Matter

MetricToday90-day target12-month targetCadence
External overdue A/R$1.30M< $500K< $250KWeekly
External A/R >90 days$422K< $150K< $50KWeekly
Open SO backlog (orders / value)691 / $3.25M< 200 / <$1M< 100 rollingDaily
Backlog aged >90 days125 orders / $1.76M00Weekly
Order-to-ship lead timeNot measured≤ 7 days≤ 5 daysWeekly
Quote → order conversion0% tracked≥ 25%≥ 35%Weekly
Qualified pipeline value$118K$1M$3MWeekly
Active buying customers (TTM)151175220Monthly
Entity-level gross margin (distribution)35–36%hold ≥ 35%≥ 37%Monthly
Mgmt fee as % of trading-entity op income122%negotiation live< 80%Quarterly
Return authorizations (value/qtr)~$45K−25%−50%Monthly
Consolidated operating income−$0.9M YTDBreakeven monthlyPositive FYMonthly

8.Next Actions & Companion Data Files

Companion data exports (delivered alongside this report)

backlog-triage-open-sales-orders.csv
All 691 open sales orders: order #, date, customer, status, value, age in days, age bucket (with "OVER 180 — CONFIRM OR CANCEL" pre-flagged), intercompany flag. Sorted oldest-first. This is the Phase-1 ops working document.
ar-aging-by-customer.csv
All 75 customers with open invoices: standard aging buckets (current / 1–30 / 31–60 / 61–90 / 91–365 / 365+), open invoice count, oldest days past due, intercompany flag. Sorted by total open descending. This is the collections war-room worksheet.

Next 11 actions (start Monday)

Interactive checklist — ticks persist in this browser via localStorage. 0 of 11 complete.

Reactivation call list — lapsed buyers by lifetime value

AccountLifetime revenueInvoicesLast purchase
Zurasky Dynamics$15,8211Sep 2025
Dabfeed Provisions$12,5523Nov 2025
Cogilith inc.$12,2123Aug 2025
Consectetuer Mauris Id LLP$11,9673Oct 2025
Bark Less Dog Training$9,0254Oct 2024
ABC Co.$8,9404Jul 2024
Cogidoo Ltd.$8,4304Jul 2025
Cogibox LP$8,3454Jun 2025
Centimia LLp$7,8143Feb 2025
Consectetuer Limited Ltd.$4,5013Sep 2025

16 lapsed buyers total ($114K lifetime). Modest individually — the bigger prize is the ~300 never-activated prospect records and share-of-wallet growth in the 151 active accounts.

The strategic thesis, updated for v3: This company doesn't have a demand problem or a margin problem — external sales grew from ~$25K to $1.1M/month in 20 months, and every trading entity is profitable at 35–60% gross margin. It has an execution-and-structure problem: ~$4.5M of earned value is trapped in overdue receivables and unshipped orders, and a $4.66M management fee erases more profit than every commercial initiative combined could add. The flywheel: collect the cash (Phase 1) → fix throughput and the funnel (Phase 2) → restructure the fee and reinvest in demand (Phase 3) → scale the proven UK/Canada model (Phase 4). Each phase funds the next; no external capital required.